Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse  >  Merck & Co., Inc.    MRK

News SummaryMost relevantAll newsSector news 

Merck Combination Cholesterol Drug Fails to Meet Study Goals; Firm Doesn't Plan to Seek U.S. Approval

12/20/2012 | 09:17am US/Eastern
   By Tess Stynes 

Merck & Co. (>> Merck & Co., Inc.) said its doesn't plan to seek U.S. Food and Drug Administration for a combination cholesterol treatment that aims to reduce the risk of cardiovascular events after the drug failed to meet primary goals in a large long-term study.

Shares were down 2.9% at $42.40 in premarket trading.

The pharmaceutical giant said it isn't recommending that health-care providers start new patients on the treatment--Tredaptive--an extended release combination of niacin and laropiprant. The company also plans to share the study results with health regulators in countries where it also is approved under the Tredaptive or Cordaptive brands.

"While we are disappointed in these results, we thank the investigators who have conducted the study and the patients who have participated in it," said Peter S. Kim, president, Merck Research Laboratories.

The study that compared extended-release niacin and laropiprant plus statin therapy versus statin therapy included 25,673 patients in Britain, Scandinavia and China considered at risk for cardiovascular issues that were followed for a median 3.9 years.

The study found that the combination drug along with statin therapy didn't significantly further reduce the risk of a combination of cardiovascular events such as nonfatal heart attacks, strokes or coronary-related deaths compared with just statin therapy. There also was an increase in nonfatal events in the group receiving Tredaptive.

Further analysis is under way and detailed study results are expected in the first quarter.

Write to Tess Stynes at Tess.Stynes@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Merck & Co., Inc.
React to this article
Latest news on MERCK & CO., INC.
05:16p MERCK : Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for..
04:55p Pacific trade deal adds to U.S. price quandary for biotech drugs
01:45p MERCK : Health and Human Services Department (HHS); Food and Drug Administration..
10/02 SITC : New Immunotherapy for Lung Cancer Offers Hope to Patients, SITC Reacts
10/02DJFDA Approves Merck's Keytruda for Most Common Form of Lung Cancer -- Update
10/02 MERCK : FDA expands Merck drug's approval to treat lung cancer
10/02 MERCK : FDA Approves KEYTRUDA® (pembrolizumab) for the Treatment of Patients wit..
10/02DJFDA Approves Merck's Keytruda for Most Common Form of Lung Cancer
10/02DJFDA Approves Merck's Keytruda for Lung Cancer
10/02 Novartis biosimilar copycat takes aim at Amgen's drug Enbrel
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Income Statement Evolution
More Financials